Clinical Trials Logo

ASCVD clinical trials

View clinical trials related to ASCVD.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06404515 Not yet recruiting - Clinical trials for Coronary Artery Disease

Telehealth Group Counseling and Preventive Care for Women

Start date: May 24, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to utilize an innovative healthcare delivery strategy via telehealth group counseling sessions to improve engagement, adherence, and ultimately outcomes in female patients with atherosclerotic cardiovascular disease (ASCVD).

NCT ID: NCT05976893 Not yet recruiting - Cancer Clinical Trials

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Start date: August 1, 2023
Phase: Phase 4
Study type: Interventional

This study is a prospective, randomized, open-label, and single center trial. To evaluate the effect of treatment with PCSK9 inhibitor on the risk for cardiovascular death, recurrent unstable angina, myocardial infarction, stroke, or coronary revascularization in patients with very high risk of atherosclerotic cardiovascular disease (ASCVD) and cancer.

NCT ID: NCT05858879 Not yet recruiting - Clinical trials for Coronary Artery Calcification

Notification of Incidental Coronary Artery Calcium in Patients With Atherosclerotic Cardiovascular Disease (NOTIFY-ASCVD)

NOTIFY-ASCVD
Start date: July 2024
Phase: N/A
Study type: Interventional

Estimate the impact of notifying both patients and their clinicians of the presence of incidental coronary artery calcium (CAC) on initiation of lipid-lowering therapy in patients with ASCVD who are not receiving lipid-lowering therapy.

NCT ID: NCT04093440 Not yet recruiting - Metabolic Syndrome Clinical Trials

Cardiometabolic Syndrome Response to Therapeutic Lifestyle Changes

COSMETIC
Start date: October 2019
Phase: N/A
Study type: Interventional

Intensive lifestyle intervention has shown to be effective in high risk patient populations and has gathered support from leaders—as outlined in the 2015 consensus paper by the Cardiometabolic Health Alliance. Thus there has been a call to establish new care models that assist Metabolic Syndrome patients in reducing there risk. The investigators aim to evaluate the impact of a lifestyle intervention program on metabolic syndrome patients.